济南痛风病要怎么治济南痛风能喝乳酸菌饮料吗,山东得了痛风怎样治疗好,济南尿酸就会痛风吗,济南脚部痛风石,济南痛风发病原因有哪些,北京黄道益治痛风有用吗,济南膝盖出现痛风石

SAN DIEGO, Calif. – What’s usually a marathon for biotech companies is now a full-blown sprint to stop the spread of coronavirus.Kate Broderick, the Senior Vice President of R&D at Inovio Pharmaceuticals in San Diego, remembers the moment she first learned about the mysterious outbreak unfolding thousands of miles away. “Yes, absolutely, distinctly, probably one of those moments you’ll remember forever. I was in my kitchen at home the 31st of December,” said Broderick.She never imagined that two months later it would be the crisis it is today. “Every week I keep thinking it’s going to get better, it’s going to start to tone down a little bit, but in fact, rather than getting better it’s getting worse every week,” said Broderick.Inovio has made headlines before, creating vaccines for Zika, Ebola, and now the coronavirus. After Chinese researchers shared the genetic sequence of COVID-19, Inovio designed a vaccine in just three hours Using its proprietary DNA medicines platform technology. The vaccine was designed to precisely match the DNA sequence of the virus“In an outbreak setting we really don’t have two to three years to wait for a vaccine, so that’s where we come in at Inovio pharmaceuticals, we use DNA medicine technology,” said Broderick.While traditional vaccines use the virus itself, this method puts DNA inside E.coli, which naturally replicates the medicine over and over. The paste is then purified, leaving behind only the DNA medicine, which Inovio hopes to test in humans next month.“Infectious diseases are global and they don’t care about boundaries and borders, everyone is affected from childhood all the way through seniors,” said Phyllis Arthur, who’s been in the infectious disease industry for 20 years.Arthur is Vice President of Infectious Diseases and Diagnostic Policy at BIO, an association made up of about 1,000 companies.“One of the things we’re seeing, from outbreak to outbreak, unfortunately, is we’re getting faster at using platform technologies to build something that can be tried in humans sooner than we were the last time,” said Arthur.She’s following dozens of companies working on vaccines, treatments, and diagnostic tools. If their vaccines work, companies like Inovio will have to figure out how to manufacture them fast.“You may have the best vaccine in the world, but if you can only produce 1,000 doses of it, that’s not really going to help 1.4 billion people in China,” said Broderick. Continued funding will also be critical. Broderick says while their Zika vaccine looked promising in humans, it never ultimately got FDA approval for broad public use.“The problem there was, although great for global health, was that of course cases of the virus really steadily declined, the problem for us there was so did the funding,” said Broderick.She says that way of thinking is shortsighted but does see change on the horizon. “It’s a huge amount of responsibility on everyone’s shoulders, and I think we feel genuinely compelled to do everything in our power, hence why no one complains about two hours of sleep, because this is a point in our careers we can truly, literally, make a difference in saving lives, right now,” said Broderick.After the company begins human trials in the U.S., they’ll continue testing in China and South Korea. They hope to deliver one million doses by the end of the year.If they make it that far, it too would be a day Broderick will never forget. 3462

Target capped off its best year in more than a decade with a strong holiday shopping season.Sales at Target stores open at least a year grew 5 percent last year — its best performance since 2005.Target's stellar 2018 got a big boost from the holiday season. Comparable sales grew 5.3 percent during its most recent quarter compared with last year. Its digital sales grew 31 percent.The big-box retailer gained market share in key categories like clothes and home furnishings during the holidays and got a boost from the growing economy. Target said foot traffic to stores was up.Target's stock rose nearly 6% during pre-market trading Tuesday, despite thinner profit margins from fulfilling online orders. Target waived its minimum order requirement on online orders during the holidays.The gap between retail's best and worst performing companies widened during the holidays and Target is among the winners."We have been driving an ambitious agenda to transform," CEO Brian Cornell said in a news release Tuesday.The company's strategy to compete against Amazon and Walmart by focusing on Millennials and young parents with affordable brands and offering a wider array of merchandise is paying dividends.Parents are crucial to Target's success because they spend more every year than shoppers without children.Investments in its stores have helped, too. Target has aggressively remodeled hundreds of stores, built out delivery and buy-online-pickup-in-store capabilities, and built small stores to extend its reach within cities and college campuses.Target also launched more than 25 exclusive brands, such as Goodfellow, a clothing label, and A New Day, a homegoods label, that burnish its trendy image."Target's strategic initiatives announced two years ago are clearly bearing fruit, with its online push continuing to generate impressive gains," said Charlie O'Shea, analyst at Moody's.Target has succeeded recently, but a parade of top retailers reported uneven results this earnings season. Some, including Walmart, TJX and Best Buy thrived. But L Brands-owned Victoria's Secret, JCPenney and Gap struggled.Kohl's sales at stores open at least a year grew 1 percent during the holidays, the company announced Tuesday. Like Target, 2250

Sherry Ellis found out she was dead the day after Halloween.The 73-year-old from Magnolia, Texas, was picking up her prescription from Walgreens when her bank card was declined. She said she knew something was fishy because the card was three months old.So she went to the bank, and after rounds of phone calls Ellis found out she had been 352

SAN FRANCISCO (AP) — Apple has agreed to pay up to 0 million to settle claims over intentionally slowing down older phones to preserve batteries. The company will pay eligible iPhone owners each. But that amount could be reduced if too many people file claims. The case stems from admissions in 2017 that Apple was slowing down older iPhones to avoid unexpected shutdowns related to battery fatigue. Plaintiffs in the case claimed that they spent hundreds of dollars buying new phones, rather than just replacing the batteries, because Apple didn't reveal the cause of the problem. A judge still needs to approve the settlement. 647

Stocks, already rattled by the US-China trade war, were set to fall sharply Friday after President Donald Trump announced new tariffs on Mexican imports.Dow 169